LAVAL, Quebec / Aug 06, 2025 / Business Wire / Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the second quarter ended June 30, 2025 (“Q2-2025”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with... Read More

LAVAL, Quebec / Jun 05, 2025 / Business Wire / Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 4, 2025. The detailed results of the votes received by... Read More

LAVAL, Quebec / May 23, 2025 / Business Wire / Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“ Crescita ” or the “ Company ”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities, today announced that it has, by mutual agreement, terminated its commercialization and development license agreement with CROMA Pharma GmbH (“Croma”), that... Read More

LAVAL, Quebec / May 14, 2025 / Business Wire / Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the first quarter ended March 31, 2025 (“Q1-2025”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with... Read More

LAVAL, Quebec / Mar 18, 2025 / Business Wire / Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2024 (“Q4-2024” and “F2024”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted... Read More

LAVAL, Quebec / Nov 06, 2024 / Business Wire / Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the third quarter ended September 30, 2024 (“Q3-2024”). All amounts presented in this press release are in thousands of Canadian dollars (“CAD”) unless otherwise noted and... Read More

LAVAL, Quebec / Sep 24, 2024 / Business Wire / Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“ Crescita ” or the “ Company ”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced that the Toronto Stock Exchange (the “ TSX ”) has approved the Company’s proposed normal course issuer bid (“ NCIB ”) to purchase up to a maximum of 1,478,854 common shares (“ Common Shares ”)... Read More

LAVAL, Quebec / Sep 12, 2024 / Business Wire / Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced that it will be presenting and participating in 1x1 meetings at the Planet MicroCap Showcase: VANCOUVER 2024 in association with Small Cap Discoveries on Thursday, September 26, 2024 at 1:00 PM... Read More

Secures Manufacturing Contract of US$10 Million over 4 Years Completes Strategic Asset Acquisition LAVAL, Quebec / Aug 07, 2024 / Business Wire / Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the second quarter ended June 30, 2024 (“Q2-2024”). All amounts presented... Read More

LAVAL, Quebec / Jul 22, 2024 / Business Wire / Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“ Crescita ” or the “ Company ”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities, today announced the signing of an amendment to its contract manufacturer supply agreement (the “Amended Agreement”) with its largest CMO client (the “Client”), a... Read More

LAVAL, Quebec / Jul 19, 2024 / Business Wire / Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“ Crescita ” or the “ Company ”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities, today announced that it has signed an exclusive Manufacturing and Supply Agreement (the “Agreement”) with a leading Canadian diversified healthcare services... Read More

LAVAL, Quebec / Jul 17, 2024 / Business Wire / Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced that it has signed an exclusive distribution agreement (the “Agreement”) with NanoPass Technologies Ltd. (“NanoPass”), a pioneer in the development and commercialization of an advanced intradermal... Read More

LAVAL, Quebec / Jun 26, 2024 / Business Wire / Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced that it has concluded the asset purchase agreement (the “Purchase Agreement”) to acquire all of the non-real estate business assets of Occy Laboratory Inc. (“Occy”), a Laval-based manufacturer and... Read More

LAVAL, Quebec / Jun 20, 2024 / Business Wire / Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced that it has agreed to acquire all of the non-real estate business assets of Occy Laboratory Inc., (“Occy”), a Laval-based manufacturer and distributor of high-quality dermocosmetic products (the... Read More

LAVAL, Quebec / Jun 06, 2024 / Business Wire / Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 5, 2024. The detailed results of the votes received by... Read More

LAVAL, Quebec / May 08, 2024 / Business Wire / Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the first quarter ended March 31, 2024 (“Q1-2024”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted, and in accordance with... Read More

LAVAL, Quebec / Mar 13, 2024 / Business Wire / Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2023 (“Q4-2023” and “F2023”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise... Read More

LAVAL, Québec / Nov 08, 2023 / Business Wire / Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“ Crescita ” or the “ Company ”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the third quarter ended September 30, 2023 (“Q3-2023”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted. Highlights For the... Read More

LAVAL, Quebec / Aug 29, 2023 / Business Wire / Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“ Crescita ” or the “ Company ”) announced today that the Toronto Stock Exchange (the “ TSX ”) has approved the Company’s proposed normal course issuer bid (“ NCIB ”) to purchase up to a maximum of 1,821,616 common shares (“ Common Shares ”) for cancellation, representing approximately 10% of its public float as of August... Read More

LAVAL, Quebec / Aug 09, 2023 / Business Wire / Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“ Crescita ” or the “ Company ”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the second quarter ended June 30, 2023 (“Q2-2023”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted. Financial Highlights... Read More

LAVAL, Quebec / Jun 21, 2023 / Business Wire / Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 20, 2023. The detailed results of the votes received by... Read More

VIENNA , June 1, 2023 /CNW/ -- Croma-Pharma, a global player and challenger in the dynamically growing, minimally invasive aesthetics market, announces that it will launch Pliaglis ® , a topical local anaesthetic for superficial dermatological procedures, in its European core markets including Germany , the United Kingdom ("UK"), and Ireland . Further markets including Brazil will follow by the end of 2023. The anaesthetic... Read More

Strong Performance in Commercial Skincare Cash Balance of $10.3M LAVAL, Quebec / May 11, 2023 / Business Wire / Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“ Crescita ” or the “ Company ”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the first quarter ended March 31, 2023 (“Q1-F2023”). All amounts presented are in thousands of Canadian... Read More

LAVAL, Quebec / Mar 15, 2023 / Business Wire / Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“ Crescita ” or the “ Company ”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2022 (“Q4-F2022” and “F2022”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise... Read More